PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/44

A1

(11) International Publication Number: **WO 99/65488**

(43) International Publication Date: 23 December 1999 (23.12.99)

(21) International Application Number: PCT/IB99/00796

(22) International Filing Date: 3 May 1999 (03.05.99)

(30) Priority Data:
60/089,424 16 June 1998 (16.06.98) US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KE, Hua, Zhu [US/US]; 2 Deer Lane, Ledyard, CT 06339 (US). LI, Mei [CN/US]; 8 Seabury Lane, Westerly, RI 02891 (US). PAN, Lydia, Codetta [US/US]; 8 Schooner Drive, Mystic, CT 06355 (US). THOMPSON, David, Duane [US/US]; 37 Bittersweet Drive, Gales Ferry, CT 06335 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: THERAPEUTIC COMBINATIONS OF (SELECTIVE) ESTROGEN RECEPTOR MODULATORS (SERM) AND GROWTH HORMONE SECRETAGOGUES (GHS) FOR TREATING MUSCULOSKELETAL FRAILTY

(57) Abstract

This invention is directed to pharmaceutical combination compositions and methods comprising (–)–cis–6– phenyl–5–(4– (2–pyrrolidin–1– yl–ethoxy) –phenyl)– 5,6,7,8– tetrahydronaphthalene –2–ol or a pharmaceutically acceptable salt thereof and 2–amino–N–(1(R) –(2,4–difluoro– benzyloxymethyl) –2–oxo–2–(3– oxo–3a(R) –pyridin–2– ylmethyl)–2–(2,2,2–trifluoro–ethyl) –2,3,3a,4,6,7 –hexahydro –pyrazolo [4,3–c]pyridin –5–yl)–ethyl) –2–methyl–propionamide or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.